N -[7-Chloro-4-[4-(phenoxymethyl)-1 H -1,2,3-triazol-1-yl]quinoline]-acetamide

: The 1,2,3-triazole is a well-known biologically active pharmacophore constructed by the copper-catalyzed azide–alkyne cycloaddition. We herein reported the synthesis of 4-amino-7-chloro-based [1,2,3]-triazole hybrids via Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition of 4-azido-7-chloroquinoline with an alkyne derivative of acetaminophen. The compound was fully characterized by Fourier-transform infrared (FTIR), proton nuclear magnetic resonance ( 1 H-NMR), carbon-13 nuclear magnetic resonance ( 13 C-NMR), heteronuclear single quantum coherence (HSQC), ultraviolet (UV) and high-resolution mass spectroscopies (HRMS). This compound was screened in vitro with different normal and cancer cell lines. The drug likeness of the compound was also investigated by predicting its pharmacokinetic properties.


Introduction
The 7-chloroquinoline moiety, a pharmacophore of several established antimalarial drugs such as chloroquine ( Figure 1a) [1], is recently being focused on as a potential anticancer agent as well as a chemosensitizer when used in combination with anti-cancer drugs [2].
With increasing drug resistance to available agents, intensive drug discovery efforts on developing new antimalarial/anticancer drugs or modifying existing agents are ongoing [3]. Molecular hybridization as a drug discovery strategy involves the rational design of new chemical entities by the fusion (usually via a covalent linker) of two drugs, of which both active compounds and/or pharmacophoric units are recognized and derived from known bioactive molecules [3].
We have previously reported the conversion of the commercially available 4,7dichloroquinoline 1 to a series of 4-amino-7-chloroquinolone derivatives [11]. Herein, we reported the synthesis of a novel 4-amino-7-chloroquinoline-based 1,2,3-triazole hybrid 5 by Cu(I)-catalyzed azide-alkyne cycloaddition. The structure of compound 5 was characterized by NMR, MS, FT-IR and UV spectra. The cytotoxicity of 5 was also evaluated against different cell lines.
Quinoline 2 was furnished by applying the modified method reported by de Souza et al. [12], whereby 4,7-dichloroquinoline 1 reacted with two equivalents of NaN 3 in anhydrous DMF at 65 • C for 6 h (Scheme 1a). The recrystallization of the crude product from CH 2 Cl 2 /hexane afforded 2 in an 86% yield. The O-alkylation reaction of acetaminophen 3 with 1.5 equivalents of propargyl bromide and anhydrous K 2 CO 3 in anhydrous DMF yielded the acetylenic intermediate 4 in a good yield after the recrystallization from CH 2 Cl 2 /hexane (82%, Scheme 1b).
The hybrid compound 5 was finally obtained by using a modified cycloaddition procedure reported by Fokin et al. [13].
The structure of 5 was verified by 1 H and 13 C NMR spectra (Supplementary Materials, Figures S3 and S4). The 1 H-NMR spectrum showed a singlet at 5.33 ppm associated with the C13-methylene group and a singlet at 2.07 ppm associated with the α-position of the C18-carbonyl group.
Regarding the 13 C NMR signals, the disappearance of characteristic peaks of acetylenic group at 78.5 and 75.5 ppm, and the appearance of a C-13 methylene signal at 61.5 ppm and C-11 vinylic signal at 127.3 ppm were probably the most relevant features to verify the incorporation of a triazole moiety.
Heteronuclear single quantum coherence spectroscopy (HSQC) was used to assign 13 C signals of compound 5 as shown in Table S1 (see Supplementary Materials for 2D spectra, Figures S5 and S6).
The IR spectrum of compound 5 showed characteristic N-H stretching at 3448 cm −1 , C=O stretching at 1674 cm −1 and C=C stretching at 1612 cm −1 (Supplementary Materials, Figure S7). Other vibrational peaks at 1550, 1512 and 1411 cm −1 were corresponding to the N-H bending in the amide. Moreover, the absence of the azide stretching peak of 2 at 2123 cm −1 in the IR spectrum of 5 confirmed the conversion of azide.
The UV and HRMS of 5 was also recorded for further characterization (Supplementary Materials, Figures S8 and S9).
In addition, the promising compound 5 was assessed by predicting its physicochemical properties and oral bioavailability. From the calculated physicochemical properties (Supplementary Materials Table S2), compound 5 did not violate any of Lipinski's rules [14], indicating its drug-like character and a good chance for oral administration.
This finding corroborates the results of the gastrointestinal absorption from Swis-sADME, in which compound 5 was predicted with high absorption according to BOILED-Egg model [15] ( Figure S11) and data from admetSAR 2 [16], in which the compound was predicted to be orally bioavailable and absorbed in human intestine.

Chemistry
Silica gel (FCP 230-400 mesh) was used for column chromatography. Thin-layer chromatography was carried out on E. Merck precoated silica gel 60 F 254 plates and visualized with phosphomolybdic acid, iodine, or a UV-visible lamp.
All chemicals were purchased from Bide Pharmatech., Ltd. (Shanghai, China) and J & K scientific (Hong Kong, China). 1 H-NMR and 13 C-NMR spectra were collected in CDCl 3 at 25 • C on a Bruker Ascend ® -600 NMR spectrometer (600 MHz for 1 H and 150 MHz for 13 C) (Bruker, Billerica, MA, USA). All chemical shifts were reported in the standard δ notation of parts per million using the peak of residual proton signals of CDCl 3 or DMSO-d6 as an internal reference (CDCl 3 , δ C 77.2 ppm, δ H 7.26 ppm; DMSO-d6, δ C 39.5 ppm, δ H 2.50 ppm). High-resolution mass spectra (HRMS) were measured using electrospray ionization (ESI). The measurements were done in a positive ion mode (interface capillary voltage 4500 V); the mass ratio was from m/z 50 to 3000 Da; external/internal calibration was done with electrospray calibration solution.
HRMS analyses were performed by an Agilent 6230 electrospray ionization (ESI) timeof-flight (TOF) mass spectrometer with Agilent C18 column (4.6 mm × 150 mm, 3.5 µm). The mobile phase was isocratic (water +0.01% TFA; CH 3 CN) at a flow rate of 0.5 mL/min. The peaks were determined at 254 nm under UV. UV analysis was performed by a Shimadzu UV-2600 (Osaka, Japan) with 1 cm quartz cell and a slit width of 2.0 nm. The analysis was carried out using a wavelength in the range of 200-400 nm. IR analysis (KBr) was performed by a Shimadzu IRAffinity-1S (Osaka, Japan) with a frequency range of 4000-500 cm −1 .

Synthesis of 4-Azido-7-chloro-quinoline (2)
The 4,7-Dichloroquinoline (2.0 g, 10 mmol) was dissolved in 5 mL anhydrous DMF. NaN 3 (1.3 g, 20 mmol) was then added in one portion, and the resulting mixture was stirred at 65 • C for 6 h, whereupon TLC indicated reaction completion. The reaction mixture was then allowed to cool to ambient temperature, after which it was diluted with 100 mL CH 2 Cl 2 , washed with water (3 × 30 mL), dried over anhydrous Na 2 SO 4 , and evaporated to dryness. The resulting product residue was recrystallized from a CH 2 Cl 2 /hexane 1:1 mixture to yield the final pure product 2 as colorless, needle-like crystals in 86% yield.  (4) Acetaminophen (N-acetyl-para-aminophenol) (13 mmol) was dissolved in 10 mL of anhydrous DMF. Anhydrous K 2 CO 3 (2.7 g, 19.5 mmol) was then added to the solution, and the mixture was stirred at 30 • C for 30 min. Propargyl bromide (3-bromopropyne, 2.2 mL, 19.5 mmol) was then added slowly to the reaction mixture, and subsequently stirred at 30 • C for 6 h upon which TLC indicated completion of the reaction. The reaction mixture was then diluted with 50 mL water and extracted with ethyl acetate (3 × 50 mL). These extracts were then combined, washed with water (2 × 50 mL), dried over anhydrous Na 2 SO 4 and evaporated in vacuo to yield the product residue that was then recrystallized from the CH 2 Cl 2 /hexane 1:1 mixture to yield the compound 4 in 82% yield. The derivative of acetaminophen 4 (1mmol) and the appropriate azide 2 were dissolved in 5 mL tBuOH/water (1:1) and, while stirring at 65 • C, 1 M sodium ascorbate (0.4 mL, 0.4 mmol) and 1 M CuSO 4 (0.2 mL, 20 mol%) were added sequentially, in that order. The reaction mixture was then stirred at 65 • C for 24 h. The crude product was then precipitated out by slowly adding cold water to the reaction mixture, after which it was filtered, washed with water, air dried and purified by silica column chromatography (eluents ranging in polarity from EtOAc/hex 3:7 to 5% MeOH in EtOAc). Yield 72%, δ H (600 MHz, CDCl 3

Biological Studies
Compound 5 was dissolved in DMSO at a final concentration of 50 mM and stored at −20 • C before use. Cytotoxicity was assessed by using the 3-(4,5-dimethylthiazole-2yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/mL) assay as previously described [19]. Briefly, 4 × 10 3 cells per well were seeded in 96-well plates before drug treatments. After overnight cell culture, the cells were then exposed to different concentrations of selected compounds (0.19-100 µM) for 72 h. Cells without drug treatment were used as controls. Subsequently, 10 µL of 5 mg/mL MTT solution was added to each well and incubated at 37 • C for 4 h followed by addition of 100 µL solubilization buffer (10 mM HCl in solution of 10% of SDS) and overnight incubation. Then A 570 nm was determined in each well on the next day. The percentage of cell viability was calculated using the following formula: cell viability (%) = A treated /A control × 100. A representative graph of at least three independent experiments was shown in Supplementary Materials Figure S8.

Conclusions
The synthesis of a potential triazole-based quinoline was presented. The chemical structure of the synthesized compound was verified by using NMR, mass, IR and UV spectrometries. The cytotoxicity and drug likeness of the compound were also determined by MTT assay and computations, respectively.